Project-004

Document text

Principal Investigator: MADHAV V DHODAPKAR
Organization: EMORY UNIVERSITY
Fiscal Year: 2024
Award: $88,878
Funding agency: National Cancer Institute

Abstract:
The Emory U54 SeroNET U54 program is a multidisciplinary program that brings together
experienced team of investigators to tackle fundamental issues relating to immunity to
SARS CoV-2, particular in patients with cancer and autoimmunity. The team has a long
track record of prior work in basic and translational studies in the setting of viral infections,
vaccines and cancer. The program consists of 3 interacting projects and two essential
cores in addition to the administrative core. Studies in project 1 (led by Sanz) will study
the biology of SARS CoV-2 specific effector B cell responses in patients with
autoimmunity, with a particular focus on extrafollicular B cell pathway. Studies in project
2 (led by Sekaly and Wrammert) will study the role of inflammatory milieu in regulating
antiviral immunity and in the development of long term memory responses. Studies in
project 3 (led by Dhodapkar and Ahmed) will focus on studying the impact of specific
cancer therapies, in particular B/plasma cell depleting therapies in patients with B/plasma
cell malignancies, and immune checkpoint blockade in patients with lung cancer. These
studies will also set the stage for studying immune responses to future SARS CoV-2
vaccines in patients with autoimmunity as well as cancer patients. The programs are
supported by active cores (led by Roback and Neish) which have experience with
monitoring immunity to SARS CoV-2. Together, this program will not only provide basic
insights into immune-pathogenesis of COVID, but also provide the consortium with
access to unique patient populations at higher risk of COVID-related mortality.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Ab response><Acute><Address><Administrative Supplement><African American><Afro American><Afroamerican><Antibody Formation><Antibody Production><Antibody Response><Antitumor Response><Autoimmune><Autoimmune Diseases><Autoimmune Status><Autoimmunity><B blood cells><B cell><B cell malignancy><B cells><B lymphoid malignancy><B-Cells><B-Lymphocytes><B-cell><Biology><Blood Plasma Cell><COVID disease severity><COVID severity><COVID-19><COVID-19 associated death><COVID-19 associated fatality><COVID-19 associated mortality><COVID-19 death><COVID-19 disease severity><COVID-19 fatality><COVID-19 immunity><COVID-19 induced death><COVID-19 induced fatality><COVID-19 induced mortality><COVID-19 infection><COVID-19 mortality><COVID-19 pathogenesis><COVID-19 related death><COVID-19 related fatality><COVID-19 related mortality><COVID-19 severity><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID-19 virus infection><COVID19 associated death><COVID19 associated fatality><COVID19 associated mortality><COVID19 death><COVID19 disease severity><COVID19 fatality><COVID19 induced death><COVID19 induced fatality><COVID19 induced mortality><COVID19 infection><COVID19 mortality><COVID19 pathogenesis><COVID19 related death><COVID19 related fatality><COVID19 related mortality><COVID19 severity><COVID19 virus><CV-19><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cells><Clinical><CoV-2><CoV2><Coronavirus Infectious Disease 2019><Data Set><Defect><Development><Disease><Disorder><ELISA><Ensure><Enzyme-Linked Immunosorbent Assay><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Equilibrium><Future><Gene Transcription><Generations><Genetic Transcription><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Heterogeneity><Immune><Immune Monitoring><Immune response><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Monitoring><Immunological><Immunological Monitoring><Immunological response><Immunologically><Immunologics><Immunology><Immunomodulation><Immunomonitoring><Impairment><Inflammation><Inflammatory><Innate Immune Response><Investigators><Length of Life><Longevity><Lupus Erythematosus Disseminatus><Malignant><Malignant - descriptor><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Measures><Mediating><Memory B Cell><Memory B-Lymphocyte><Minority><Molecular><Monitor><Muscle Paresis><Muscular Paresis><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Nature><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Outcome><Paresis><Pathogenicity><Pathway interactions><Patients><Plasma Cells><Plasmacytes><Population><Population Programs><Pulmonary Cancer><Pulmonary malignant Neoplasm><RNA Expression><Regulation><Research><Research Personnel><Researchers><Risk><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 associated death><SARS-CoV-2 associated fatality><SARS-CoV-2 associated mortality><SARS-CoV-2 death><SARS-CoV-2 disease severity><SARS-CoV-2 fatality><SARS-CoV-2 immunity><SARS-CoV-2 induced death><SARS-CoV-2 induced fatality><SARS-CoV-2 induced mortality><SARS-CoV-2 infection><SARS-CoV-2 mortality><SARS-CoV-2 related death><SARS-CoV-2 related fatality><SARS-CoV-2 related mortality><SARS-CoV-2 severity><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SLE><Sampling><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Systemic Lupus Erythematosus><Systemic Lupus Erythematous><Systemic Lupus Erythmatosus><T cell response><T-Cells><T-Lymphocyte><Target Populations><Technology><Transcription><Tumor Antigens><Tumor-Associated Antigen><University Hospitals><Vaccines><Viral><Viral Diseases><Virus><Virus Diseases><Work><Wuhan coronavirus><acute COVID-19><acute SARS-CoV-2 infection><acute phase of COVID-19><acute phase of SARS-CoV-2 infection><adaptive immune response><after COVID-19 infection><after SARS-CoV-2 infection><after SARS-CoV2 infection><after infection by SARS-CoV-2><after severe acute respiratory distress syndrome CoV-2 infection><anti-cancer therapy><anti-tumor response><anti-viral immunity><antibody biosynthesis><antiviral immunity><autoimmune condition><autoimmune disorder><autoimmunity disease><balance><balance function><cancer antigens><cancer therapy><cancer-directed therapy><check point blockade><checkpoint blockade><coronavirus disease 2019><coronavirus disease 2019 associated death><coronavirus disease 2019 associated fatality><coronavirus disease 2019 associated mortality><coronavirus disease 2019 death><coronavirus disease 2019 disease severity><coronavirus disease 2019 fatality><coronavirus disease 2019 immunity><coronavirus disease 2019 induced death><coronavirus disease 2019 induced fatality><coronavirus disease 2019 induced mortality><coronavirus disease 2019 infection><coronavirus disease 2019 mortality><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 related death><coronavirus disease 2019 related fatality><coronavirus disease 2019 related mortality><coronavirus disease 2019 severity><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 mortality><coronavirus disease-19 pathogenesis><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><death due to COVID-19><death due to COVID19><death due to SARS-CoV-2><death due to coronavirus disease 2019><death due to severe acute respiratory syndrome coronavirus 2><death in COVID><death in COVID-19><death in SARS-CoV-2><death in coronavirus disease><death in coronavirus disease 2019><death in severe acute respiratory syndrome coronavirus 2><density><depository><developmental><disseminated lupus erythematosus><enzyme linked immunoassay><epigenetically><experience><fatality due to COVID-19><fatality due to COVID19><fatality due to SARS-CoV-2><fatality due to coronavirus disease 2019><fatality due to severe acute respiratory syndrome coronavirus 2><following COVID-19 infection><following SARS-CoV-2 infection><following SARS-CoV2 infection><following infection by SARS-CoV-2><following severe acute respiratory distress syndrome CoV-2 infection><hCoV19><high risk><host response><immune check point blockade><immune checkpoint blockade><immune modulation><immune regulation><immune system response><immunity against COVID-19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunoglobulin biosynthesis><immunologic reactivity control><immunomodulatory><immunopathology><immunoregulation><immunoregulatory><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><inflammatory environment><inflammatory milieu><insight><interest><long term memory><longterm memory><lung cancer><malignancy><mortality due to COVID-19><mortality due to COVID19><mortality due to SARS-CoV-2><mortality due to coronavirus disease 2019><mortality due to severe acute respiratory syndrome coronavirus 2><multidisciplinary><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neoplasm/cancer><neutralizing antibody><paretic><paretic muscle><pathogenic autoantibodies><pathway><patient population><plasmocyte><post SARS-CoV-2 infection><previous COVID-19 infection><previous SARS-CoV-2 infection><previous SARS-CoV2 infection><previous severe acute respiratory distress syndrome CoV-2 infection><prior COVID-19 infection><prior SARS-CoV-2 infection><prior SARS-CoV2 infection><prior severe acute respiratory distress syndrome CoV-2 infection><programs><prospective><rate of infection><recruit><repository><response><serology surveillance><serosurveillance><severe acute respiratory syndrome coronavirus 2 associated death><severe acute respiratory syndrome coronavirus 2 associated fatality><severe acute respiratory syndrome coronavirus 2 associated mortality><severe acute respiratory syndrome coronavirus 2 death><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 fatality><severe acute respiratory syndrome coronavirus 2 induced death><severe acute respiratory syndrome coronavirus 2 induced fatality><severe acute respiratory syndrome coronavirus 2 induced mortality><severe acute respiratory syndrome coronavirus 2 mortality><severe acute respiratory syndrome coronavirus 2 related death><severe acute respiratory syndrome coronavirus 2 related fatality><severe acute respiratory syndrome coronavirus 2 related mortality><severe acute respiratory syndrome coronavirus 2 severity><social role><success><systemic lupus erythematosis><thymus derived lymphocyte><translational study><tumor><tumor-specific antigen><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><viral infection><virus infection><virus-induced disease>